Completed PHASE4 INTERVENTIONAL 2-arm NCT03402815

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

Sponsor: University Of Perugia

Conditions Atherosclerosis Cardiovascular Risk Factor HIV Infection With Other Conditions Inflammation

Updated 5 times since 2018 Last updated: Jan 19, 2018 Started: Jan 1, 2015 Primary completion: Apr 30, 2017 Completion: Sep 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03402815, this PHASE4 trial focuses on Atherosclerosis and Cardiovascular Risk Factor and remains completed. Sponsored by University Of Perugia, it has been updated 5 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2018 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Of Perugia

Data source: University Of Perugia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Perugia, Italy